Biomerica Inc (BMRA) Return on Equity ROE from the fourth quarter 2026 to fourth quarter 2025 and annually, average high and low, overall ranking from May 31 2026 to May 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Biomerica Inc   (NASDAQ: BMRA)

Biomerica Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Biomerica Inc in the fourth quarter 2026?
Biomerica Inc recorded a cumulative net loss of $-4 million during 12 months ending in the fourth quarter 2026, resulting in a negative return on equity (ROE) of -99.3%.

Within the In Vitro & In Vivo Diagnostic Substances industry 9 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2026 from 2040 to 3493.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (May 31 2026)
IV. Quarter		 (Feb 28 2026)
III. Quarter		 (Nov 30 2025)
II. Quarter		 (Aug 31 2025)
I. Quarter		 (May 31 2025)
IV. Quarter
Y / Y Equity Change -35.93 % -40.06 % -37.72 % -3.57 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -4 -4 -4 -4 -5
Return On Equity (TTM) -99.3 % -100.08 % -85.19 % -68.37 % -92.2 %
BMRA's Total Ranking # 3493 # 2040 # 2535 # 62 # 2987
Equity (TTM) in Millions 3 3 4 5 4
Seq. Equity Change -20.71 % -19.2 % -20.37 % 25.58 % -25.82 %
Seq. Net Income Change - - - - -

Back to BMRA Management Effectiveness >> BMRA's 5 Years Annual ROE >> Compare BMRA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 10
Sector # 552
Overall # 3493

Return On Equity Statistics
High Average Low
15.95 %
-55.77 %
-100.08 %
(May 31 2017)   (Feb 28 2026)





BMRA Annual Return On Equity (May 31 2026)
2026		 (May 31 2025)
2025		 (May 31 2024)
2024		 (May 31 2023)
2023		 (May 31 2022)
2022
Total Equity in Millions 3 4 7 12 8
Y / Y Equity Change -35.93 % -37.72 % -43.78 % 40.83 % -9.78 %
Net Income in Millions -4 -5 -6 -7 -5
Y / Y Net Income Change - - - - -
Return On Equity -143.54 % -121.14 % -90.7 % -60.9 % -54.43 %

Back to BMRA Management Effectiveness >> BMRA's 5 Years Annual ROE >> Compare BMRA ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BMRA's' Return on Equity at Yahoo Finance
BMRA's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BMRA's Competitors
Subscribers only: Roe for Biomerica Inc 's Suppliers
Subscribers only: Return On Equity for BMRA's Customers




Companies with similar Return On Equity at May 31 2026, within Healthcare Sector ROE

Date modified: 2026-09-05T08:34:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.